Discover GET 2024
The GET meeting is an annual educational initiative supported by Novartis. Since its launch 15 years ago, GET has provided a valuable educational platform and opportunity for haematologists to interact with colleagues and enhance patient care.
GET 2024 was developed by an independent scientific steering committee to bring you the latest clinical updates on a diverse range of topics in haematology, delivered by prominent speakers. We thank all the speakers for providing access to the content presented at the meeting.
Session Recordings
Lymphoma: Emerging therapeutic landscape
Presented by Dr Mark Dowling
Tisagenlecleucel for relapsed/refractory large B cell lymphoma: The Royal Prince Alfred Experience
Presented by Dr Edward Abadir
CAR-T Therapy for adults with B-ALL in Australia
Presented by Dr Shaun Fleming
CAR-T in Myeloma
Presented by Dr Jason Butler
ITP management - 2024
Presented by Dr Robert Bird
Paroxysmal nocturnal haemoglobinuria: Where are we going
Presented by Prof. Jeff Szer
Case Study Presentations
Presented by Dr Danny Hsu
Management of Polycythaemia Vera: A Community Haematologist’s Experience
Presented by Dr Cecily Forsyth
New Approaches to Managing MF
Presented by Dr Paul Yeh
State of the Art Diagnostics, Molecular Prognostication and Management of MPNs
Presented by Dr Courtney Tate
CML Highlights from ASCO & EHA 2024
Presented by Prof. Tim Hughes
The Evolving landscape of frontline CP-CML therapy Challenges in TKI selection
Presented by A/Prof. David Yeung
Asciminib outcomes in RWE
Presented by A/Prof. Lynette Chee
Role of residual disease in Granulocytes and T cells in predicting relapse risk in CML patients stopping therapy
Presented by Dr Ilaria Pagani
Asciminib Case Studies
Presented by Dr Naranie Shanmuganathan
Recent Advancements and Challenges in AML including Novel Therapies
Presented by Dr Chun Fong
The Role of MRD as a Predictive Biomarker to Guide Therapy in AML
Presented by Dr Ing Soo Tiong
Slide Presentations
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au.
Unpublished work in some of the presentations has been omitted. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
Lymphoma: Emerging therapeutic landscape
Dr Mark Dowling
Tisagenlecleucel for relapsed/refractory large B cell lymphoma: The Royal Prince Alfred Experience
Dr Edward Abadir
CAR-T Therapy for adults with B-ALL in Australia
Dr Shaun Fleming
CAR-T in Myeloma
Dr Jason Butler
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au.
Unpublished work in some of the presentations has been omitted. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
ITP management - 2024
Dr Robert Bird
Paroxysmal nocturnal haemoglobinuria: Where are we going
Prof. Jeff Szer
Case Study Presentations
Dr Danny Hsu
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au.
Unpublished work in some of the presentations has been omitted. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
Management of Polycythaemia Vera: A Community Haematologist’s Experience
Dr Cecily Forsyth
New Approaches to Managing MF
Dr Paul Yeh
State of the Art Diagnostics – Molecular Prognostication and Management of MPNs
Dr Courtney Tate
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au.
Unpublished work in some of the presentations has been omitted. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
CML Highlights from ASCO & EHA 2024
Prof. Tim Hughes
The Evolving landscape of frontline CP-CML therapy Challenges in TKI selection
A/Prof. David Yeung
Asciminib outcomes in RWE
A/Prof. Lynette Chee
Role of residual disease in Granulocytes and T cells in predicting relapse risk in CML patients stopping therapy
Dr Ilaria Pagani
Asciminib Case Studies
Dr Naranie Shanmuganathan
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au.
Unpublished work in some of the presentations has been omitted. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
Recent Advancements and Challenges in AML including Novel Therapies
Dr Chun Fong
The Role of MRD as a Predictive Biomarker to Guide Therapy in AML
Dr Ing Soo Tiong
Abbreviations: ALL (Acute lymphoblastic leukaemia); ITP (Immune thrombocytopenia); PNH (Paroxysmal nocturnal hemoglobinuria); MPN (Myeloproliferative neoplasms); CML (Chronic myeloid leukemia); AML (Acute myeloid leukemia)
Medical Information Service
Medical Enquires, Information services, Adverse Events and Product Complaints please contact:
Telephone: 1800 671 203
Mail: [email protected]
Colleagues are available from 9:00 to 17:00 from Monday to Friday